Could CAR-T Cell Therapy Reset the Immune System?

This project was made achievable thanks to the support from our Go With Us to conferences program. AiArthritis patient leaders have been attending in person and online sessions, alongside rheumatologists and researchers, to learn more about these new treatments.


Debrief Video by: Leila P.L. Valete, Health Education Manager at AiArthritis

Imagine a world where one single treatment could "reset" your immune system, helping you reach long-term remission—without daily medications. That’s exactly what  researchers are exploring through CAR-T cell therapy and other forms of cell therapy, and the science is advancing fast. At the 2025 European Alliance of Associations for Rheumatology (EULAR) annual scientific congress in Barcelona, Health Education Manager and person living with an AiArthritis disease, Leila attended a full session dedicated to this exciting research in autoimmune and autoinflammatory disease care.


Here is a breakdown on what we learned at EULAR 2025:

What Is CAR-T Cell Therapy?

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. It was first developed for cancer, where it showed remarkable success. Now, scientists are bringing it into the autoimmune world. Here's how it works:


  • Step 1: Remove immune cells (T cells) from your blood.
  • Step 2: Genetically engineer those cells in a lab to attack malfunctioning immune cells (like B cells).
  • Step 3: Use a chemotherapy drug to clear out existing B cells in your body (this temporarily weakens the immune system).
  • Step 4: Re-infuse your engineered T cells back into your body in a single treatment.
  • Step 5: Monitor recovery in the hospital (usually 2 weeks), and wait for your immune system to rebuild in a more balanced, less self-attacking way.


This approach is often referred to as “resetting the immune system.”


Why It Matters for Autoimmune Patients

Autoimmune diseases like lupus and systemic sclerosis (scleroderma) cause the immune system to mistakenly attack healthy tissues. Traditional treatments often involve ongoing immune suppression. But CAR-T therapy offers a whole new approach: retraining your immune system to behave properly again.


So far, most autoimmune trials have focused on:


  • Lupus
  • Systemic sclerosis/Scleroderma
  • Myositis (closely related but not under AiArthritis)

What’s New This Year?

Since last year’s updates at ACR, the research has exploded. Here’s what’s new:


1. “Off-the-Shelf” Cell Therapies Are Coming


Normally, CAR-T therapy requires creating cells from your own body—a lengthy and expensive process. Now, researchers are developing allogeneic (donor-based) or “off-the-shelf” CAR-T cells:


  • Made from healthy donor cells
  • Can be stored and used as needed
  • Less waiting time
  • Potentially more affordable and scalable


2. Drug-Free Remission Is Becoming Real


One patient with lupus has remained in drug-free remission for 4 years after a single CAR-T treatment. Another cancer patient was featured who has been in remission for 10+ years. While not yet considered a "cure," long-term remission is a huge breakthrough.


3. Safety Is Improving


While the process is intensive, most side effects are short-term and manageable:


  • Temporary use of steroids
  • Cytokine release syndrome (a type of immune reaction), usually mild
  • Local rashes or inflammation
  • Immune system recovery (especially B cells) happens quickly

Limitations You Should Know

  • Still Experimental: These therapies are currently only available through clinical trials.
  • Complex Process: Requires hospital stay, immune suppression, and careful monitoring.
  • Not a Cure: While remission is possible, it’s not guaranteed—and more data is needed.
  • Not Yet Widely Available: We're likely still a few years away from widespread access, though it’s progressing fast.

What Could This Mean for You?

Even if you’re not in one of the first clinical trial groups, this research gives us hope for the future. Here’s how it might impact your disease journey:


  • A single treatment instead of lifelong medications
  • More precise, personalized care
  • Fewer side effects from long-term immune suppression
  • Potential application to other AiArthritis diseases in the future


One exciting note: the team also mentioned ITP (immune thrombocytopenia) as a future target. I personally had ITP as a child, and it was a precursor to my lupus. It’s incredible to think that CAR-T might one day help people before full autoimmune disease develops.


Looking Ahead

We’re watching closely as this therapy expands beyond lupus and systemic sclerosis. The hope is that it can be adapted for more AiArthritis diseases—possibly within the next 5–10 years.


Thanks to Bristol Myers Squibb for sponsoring our “Go With Us” program so we can keep bringing you these updates. We’re proud to help you stay informed and empowered every step of your journey.


Read More About CAR-T Cell Therapy

DNA strand, blue and purple hues, microscopic view of genetic material.
October 8, 2025
Discover 3 breakthrough CAR-T therapy studies that are redefining treatment and advancing the future of AiArthritis diseases.
Picture of a cell with a target on it
April 8, 2025
Cell therapy involves using a patient’s own cells or donor cells to reset the immune system.
IV drip bag hanging on a stand in a softly lit hospital room
May 30, 2026
Explore the latest discussion on early treatment for rheumatoid arthritis and what current research reveals about diagnosis, intervention, and long-term patient outcomes.
Woman in a white blazer seated at a vanity, holding a makeup mirror in a softly lit room.
May 30, 2026
Discover the latest research on rheumatoid arthritis, including insights into disease risk, the importance of early treatment, and the connection between RA and lung disease.
Person seated on a chair, clutching a glowing red knee in pain
May 29, 2026
Explore what emerging research is teaching us about difficult-to-treat and poly-refractory rheumatoid arthritis, including the challenges patients face when treatments stop working and the search for more personalized approaches to care.
Older man using a tablet at a desk in a bright home office
May 29, 2026
Learn about VEXAS syndrome, a newly identified inflammatory condition linked to immune system dysfunction, and why greater awareness may help patients with complex or overlapping AiArthritis disease symptoms find answers sooner.
More Posts